Physicians, researchers and trainees from Winship Cancer Institute of Emory University will lead sessions and present cutting-edge research at the 64th American Society of Hematology (ASH) Meeting and Exposition, taking place in New Orleans, Dec. 10-13, 2022.
With more than 18,000 members from nearly 100 countries, ASH is the world's largest professional society serving clinicians and scientists who are working to conquer blood diseases. The 2022 in-person annual meeting will be broadcast virtually, and access to the meeting's virtual platform is included with registration.
"The breadth of Winship science presented at ASH really highlights how impactful Winship investigators have been in advancing research and new therapies for blood disorders and blood cancers," said Winship hematologist and researcher David A. Frank, MD, PhD, director of the Division of Hematology in Emory University School of Medicine's Department of Hematology and Medical Oncology. "Our faculty members are also playing a major role in educational and mentorship programs, and training the next generation of hematologists is an equally important endeavor."
Winship presenters will participate in 72 sessions, beginning with more than a dozen pre-conference workshops and ASH-a-Palooza trainee activities on Dec. 9. Oral and poster presentations will describe emerging pre-clinical and clinical hematologic data from Winship teams and colleagues from Emory University School of Medicine, Georgia Institute of Technology and Aflac Cancer and Blood Disorders Center of Children's Healthcare of Atlanta.
Research selected for presentation at ASH represents some of the latest preclinical and clinical data from Winship-led studies in leukemia, lymphoma, multiple myeloma and other blood disorders. Sessions will feature pioneering Winship technology and approaches, including those that aim to: improve the delivery of CAR T cell therapy; prevent graft-vs-host disease in patients who receive autologous stem cell transplantation; enhance personalized medicine in childhood cancer using the Pediatric Single Cell Cancer Atlas; and assess anemia and other malignant and benign hematologic disorders in resource-limited settings.